CDK7 and prostate carcinoma: Particularly intriguing are preclinical prostate cancer models where CDK7 inhibition with the newly identified inhibitor THZ1 attenuates AR signaling and eradicates hormone-sensitive and enzalutamide refractory prostate cancer cells [60,125,126].